Drug profile · INN
eptifibatide
EPTIFIBATIDE ACCORD
eptifibatide (EPTIFIBATIDE ACCORD) is a integrin alpha-iib/beta-3 inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Drug details — eptifibatide
- US status
- approved
- Class
- Blood and blood forming organs (B01)
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
eptifibatide (EPTIFIBATIDE ACCORD) is a integrin alpha-iib/beta-3 inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Integrin alpha-IIb/beta-3 inhibitor
Primary target: Integrin alpha-IIb/beta-3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is eptifibatide?
eptifibatide (EPTIFIBATIDE ACCORD) is a integrin alpha-iib/beta-3 inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for eptifibatide?
EPTIFIBATIDE ACCORD is a marketed brand name for eptifibatide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of eptifibatide?
eptifibatide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.